Dilated
cardiomyopathy is a condition strongly related to heart attacks, in
which the ventricles are enlarged, resulting in a thinning of cardiac
walls, and insufficient pumping of blood. Dilated cardiomyopathy can
occur at any age, though it is most common in the 20-40 demographic.
One of the major reasons of dilated cardiomyopathy is genetic. Some
other factors that can cause dilated cardiomyopathy are thyroid
disorders, viral infections of the heart, diabetes, alcoholism, and
heart valve malformations.
Browse Full Global
Dilated Cardiomyopathy Therapeutics Market Report With Complete TOC @
http://www.transparencymarketresearch.com/dilated-cardiomyopathy-market.html
Angiotensin II
Receptor Blockers Held Largest Share of Dilated Cardiomyopathy
Therapeutics Market in 2013 by Revenue
The dilated
cardiomyopathy therapeutics market worldwide is segregated on the
basis of drug class, pipeline drugs, and geography. The dilated
cardiomyopathy therapeutics market globally in terms of drug class is
broadly classified as angiotensin-converting enzyme (ACE) inhibitors,
beta blockers, aldosterone antagonists, and angiotensin II receptor
blockers (ARBs). Of all the drug class, angiotensin II receptor
blockers held the largest share of the dilated cardiomyopathy
therapeutics market in 2013 by revenue, followed by beta blockers.
The high demand for
the leading drugs for the treatment of dilated cardiomyopathy from
developed regions such as Europe and North America is a reason for
the large market shares of these classes of drugs. When used in
combination either with ACE or ARBs, aldesterone antagonist drugs
have proven to have a positive impact on the reduction of progressive
conditions such as Duchenne muscular dystrophy (DMD).
The global dilated
cardiomyopathy therapeutics market was worth US$651.0 million in
2013. By 2020, the global dilated cardiomyopathy therapeutics market
is projected to be worth US$328.6 million which shows a decline of 7%
CAGR from 2014 to 2020.
Clinical Trials May
Halt Expected Reduction of Dilated Cardiomyopathy Therapeutics Market
The dilated
cardiomyopathy therapeutics market worldwide is driven by growing
incidence of congestive heart failure which is significantly related
with DCM. On a global scenario, dilated cardiomyopathy is associated
to 30% to 40% for congestive heart failure cases every year. Due to
the growing incidence of congestive heart failure worldwide, several
companies have initiated clinical trials for the advancement of
therapeutics for dilated cardiomyopathy.
Some of the clinical
trials undertaken are a phase II study by Array BioPharma in 2015 for
its drug class ARRY-371797, a phase II study by Celladon Corporation
in 2014 for its drug class MYDICAR. The dilated cardiomyopathy
therapeutics market is expected to get a boost on the successful
completion of these clinical trials. However, implantable devices
such as heart pumps, pacemakers, and advancement in gene therapy will
restrain the growth of dilated cardiomyopathy therapeutics market.
Browse Full Press
Release Report :
North America Leads
Global Dilated Cardiomyopathy Therapeutics Market
According to
geographical segmentation, the dilated cardiomyopathy therapeutics
market is divided into four regions, which are Asia Pacific, Europe,
North America, and Rest of the World (RoW). North America held the
largest share of the dilated cardiomyopathy therapeutics market in
2013 owing to rising cases of heart diseases and acceptance for
branded drugs.
The U.S. and Canada
make up the dilated cardiomyopathy therapeutics market in North
America. The prevalence of DCM in the U.S. is high; 5-8 people out of
every 100,000 are diagnosed with DCM. In Canada, heart failure
accounts for 9% of total deaths in the country, which is driving the
dilated cardiomyopathy therapeutics market in North America.
In Europe, countries
such as Spain, Germany, the U.K., and Italy contribute significantly
towards the growth of the dilated cardiomyopathy therapeutics market.
The dilated cardiomyopathy therapeutics market is growing in Asia
Pacific and Rest of the World (RoW) owing to rising economic power,
higher incomes, and growing demand for generic drugs.
Some of the key
players in the dilated cardiomyopathy therapeutics market are Teva
Pharmaceutical Industries Ltd , Merck & Co., Inc., Array
BioPharma, Inc., Celladon Corporation, GlaxoSmithKline plc, Pfizer,
Inc., Janssen Pharmaceuticals, Inc., Novartis International AG,
Sanofi S.A., AstraZeneca plc and Vericel Corporation.
Request a Brochure
of this Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=2293
About Us
Transparency Market
Research is a global market intelligence company, providing global
business information reports and services. Our exclusive blend of
quantitative forecasting and trends analysis provides forward-looking
insight for thousands of decision makers. Our experienced team of
Analysts, Researchers, and Consultants, use proprietary data sources
and various tools and techniques to gather, and analyze information.
Our data repository
is continuously updated and revised by a team of research experts, so
that it always reflects the latest trends and information. With a
broad research and analysis capability, Transparency Market Research
employs rigorous primary and secondary research techniques in
developing distinctive data sets and research material for business
reports.
Contact
Mr. Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll
Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
http://www.transparencymarketresearch.com
No comments:
Post a Comment